Reading Time: 3 minutesPromising results from a Phase II clinical trial for a drug called NP001 have been announced by the biopharmaceutical company Neuraltus. The trial, conducted in America, suggested
Category: Treatments
Reading Time: 2 minutesSadie’s recent post on the emerging partnership between Peakdale Molecular and the Sheffield Institute for Translational Neuroscience prompted me to say a little about last month’s
Reading Time: 2 minutesThanks to funding and some strategic ‘match-making’ by the MND Association, a new drug may have taken one step closer to beginning clinical trials in
Reading Time: 3 minutes“After a time where patients and sponsors of trials alike had become disheartened about the lack of positive clinical trials, it is exciting to see
Reading Time: 2 minutesIn December last year, we told you about a new drug for uncontrollable laughter and crying (known as the pseudobulbar affect) called Nuedexta that had been approved for
Reading Time: 9 minutesI’m sure many of you who follow our blog have also been following the discussion on our forum about the Neuraltus trial for a drug called NP001.
Reading Time: 3 minutesWe are aware that a number of MND organisations, forums and people living with MND have received spam messages regarding a gentleman who claims that
Reading Time: < 1 minuteI’m glad to finally announce that UK recruitment for the dexpramipexole clinical trial is now open! So far, we are aware that Liverpool has opened
Reading Time: 2 minutesWe have been made aware that there’s a new kid on the block in terms of unproven treatments, which is a new route of administration
Reading Time: < 1 minuteWe’re aware that thing’s may seem quiet in terms of ‘big’ MND research moments… almost too quiet… Well, today, the pharmaceutical companies Biogen Idec and Knopp Biosciences announced